Javier Molina Cerrillo: Liver Metastases in Advanced UC – Does Immunotherapy Make a Difference?
Javier Molina Cerrillo/LinkedIn

Javier Molina Cerrillo: Liver Metastases in Advanced UC – Does Immunotherapy Make a Difference?

Javier Molina Cerrillo, Attending Physician in Medical Oncology at Hospital Ramón y Cajal, shared a post on LinkedIn:

“In urothelial tumors, liver metastases are associated with a worse prognosis for our patients.

In this new real-world study from the ARON group, we analyzed the behavior of immunotherapy in this setting.

In one hand cohort 1, patients receiving pembrolizumab after planinum based chemotherapy progression, in the other hand cohort 2 patients receiving maintenance avelumab.

Both immunotherapies demonstrated improved outcomes compared with historical chemotherapy data.”

Title: Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?

Authors: Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, Tarek Taha, Enrique Grande, Kirstin Binz, Ravindran Kanesvaran, Alina Pirstuk, Ondrˇej Fiala, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Alessandro Rizzo, Renate Pichler, Zin W. Myint, Alexandr Poprach, Gaetano Facchini, Melichar Bohuslav, Hana Studentova, Franco Morelli, Tomas Buchler, Alessia Mennitto, Deniz Tural, Luigi Formisano, Inmaculada Orejana, Martina Catalano, Sebastiano Buti, Fernando Sabino Marques Monteiro, Andrey Soares, Shilpa Gupta, Francesco Massari, Matteo Santoni

Read the Full Article.

Javier Molina Cerrillo: Liver Metastases in Advanced UC - Does Immunotherapy Make a Difference?

Other articles about Urothelial Carcinoma on OncoDaily.